SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$579M
Q2 2021
Positions
34
Filings on Record
31
2019–present window
Filed
Aug 16, 2021
original filing

Summary

Lion Point Capital, LP reported $579M in U.S.-listed holdings across 34 positions for Q2 2021.

Its largest position, Marinus Pharmaceuticals, represents 11.3% of the portfolio.

Compared with Q1 2021, the fund opened 6 new positions and exited 3.

Portfolio Metrics

Turnover
+13.0%
vs prior filed quarter
Top-10 Concentration
+56.4%
share of reported value
Largest Position
+11.3%
Marinus Pharmaceuticals
New / Exited
6 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 57.5%ETP: 23.8%Other: 18.7%
  • Common Stock · 57.5% · $333M
  • ETP · 23.8% · $138M
  • Other · 18.7% · $108M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CNPCENTERPOINT ENERGY INCNEW+975.0K975.0K+$24M$24M
CPE*CALLON PETROLEUM CONEW+250.0K250.0K+$14M$14M
FORTRESS VALUE ACQUISITIN IVNEW+500.0K500.0K+$5M$5M
INNOVIZ TECHNOLOGIES LTDNEW+400.0K400.0K+$4M$4M
FORTRESS VALUE ACQUISI CORPNEW+230.7K230.7K+$2M$2M
ORIGIN MATERIALS INCNEW+100.0K100.0K+$804,000$804,000
COLLECTIVE GROWTH CORPSOLD OUT−400.0K0−$4M$0
OVVOVINTIV INCSOLD OUT−90.1K0−$2M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

29 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MARINUS PHARMACEUTICALS INCCOM NEW11.26%$65M3.63M
2ARCONIC CORPORATIONCOM7.86%$45M1.28M
3SWCHFSIERRA WIRELESS INChistory →COM7.04%$41M2.14M
4LIBERTY GLOBAL PLCSHS CL A · SHS CL C5.98%$35M1.27M
50LSBURGERFI INTERNATIONAL INChistory →COM4.75%$27M2.75M
6FEFIRSTENERGY CORPhistory →COM4.50%$26M700.0K
7DRRXEURDURECT CORPhistory →COM4.31%$25M15.31M
8CNPCENTERPOINT ENERGY INChistory →COM4.13%$24M975.0K
9TGTXTG THERAPEUTICS INChistory →COM4.08%$24M609.1K
10COMPUTE HEALTH ACQUISITIN COUNIT 99/99/99992.64%$15M1.49M
11EXTRACTION OIL & GAS INCCOM2.56%$15M269.6K
12BATLBATTALION OIL CORPORATIONhistory →COM2.17%$13M936.0K
13CC NEUBERGER PRINCIPAL HOLDNUNIT 99/99/99991.73%$10M1.00M
14JAWS MUSTANG ACQUISITION CORUNIT 99/99/99991.39%$8M800.0K
151T7TRICIDA INChistory →COM1.36%$8M1.83M
16KINIKSA PHARMACEUTICALS LTDCOM CL A1.19%$7M495.7K
17EXTREXTREME NETWORKS INCCOM0.94%$5M486.8K
18FORTRESS VALUE ACQUISITIN IVUNIT 03/31/20280.86%$5M500.0K
19INNOVIZ TECHNOLOGIES LTDSHS0.73%$4M400.0K
20CSIQCANADIAN SOLAR INCCOM0.71%$4M91.9K
21LUMOS PHARMA INCCOM0.70%$4M407.2K
22NXTCEURNEXTCURE INCCOM0.42%$2M300.0K
23FORTRESS VALUE ACQUISI CORPUNIT 99/99/99990.40%$2M230.7K
24LOGCUSDLOGICBIO THERAPEUTICS INCCOM0.38%$2M500.0K
25AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.36%$2M300.0K
26OUTFRONT MEDIA INCCOM0.31%$2M75.0K
27ORIGIN MATERIALS INCCOM0.14%$804,000100.0K
28AAALCOA CORPCOM0.01%$36,0001.0K
29SCOR1EURCOMSCORE INCCOM0.00%$5,0001.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.